The UK’s Technology Strategy Board has awarded Domainex a £250,000 grant to develop of a new drug to treat several common cancers.

The drug will act by inhibiting two protein kinases, TBK1 and IKKe, which will suppress certain cancer cell lines from growing.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The aim of the project is to identify a drug candidate that is effective in disease models and would be orally well-absorbed by humans.

Domainex research director Trevor Perrior said that the novel mode of action will allow the treatment of patients with drug-resistant, triple-negative tumours.

The marketing of the new drug will be done in partnership with a large pharmaceutical company that has the ability to conduct drug trials, Domainex said.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact